Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid for Bone Loss in Breast Cancer
NCT00022087Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Dec 2001
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in osteoporosis (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Bone mineral density in the lumbar spine at 12 months. Started Dec 2001; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00022087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022087.